Climb Bio (CLYM) Stock: Buy, Sell, or Hold?
CLYM - Climb Bio, Inc. Common Stock
$14.25
-0.70 (-4.68%)
âŧ
5d:
-2.33%
30d:
-0.97%
90d:
+30.61%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CLYM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLYM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLYM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLYM is currently trading at $14.25, which is considered slightly low relative to its 30-day fair value range of $13.54 to $16.67.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $13.09, while resistance sits at $16.17. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CLYM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.57 (+93.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $13.09, while resistance sits at $16.17. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CLYM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.57 (+93.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$13.54 -
$16.67
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 93.5% below Wall St target ($27.57)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.54 -
$16.67
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.09
Resistance Level
$16.17
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.21
Wall Street Target
$27.57
(+93.5%)
Share & Embed Analysis
Last updated: September 13, 2026 9:30 PM ET
Data refreshes hourly during market hours. Next update: 10:30 PM
Data refreshes hourly during market hours. Next update: 10:30 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLYM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
